NL-OMON46064
Completed
Not Applicable
A single-center, randomized, double-blind, two-period cross-over study to investigate the effect of a single intravenous dose of rifampicin on the pharmacokinetics of ACT-246475 in healthy subjects. - CS0310 (ID-076-106)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Idorsia Pharmaceuticals Ltd
- Enrollment
- 14
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy male and female subjects aged between 18 and 65 years (inclusive) with a Body mass index (BMI) of 18\.0 to 30\.0 kg/m2 (inclusive) at Screening.;Further inclusion criteria can be found in the protocol section 3\.2\.2
Exclusion Criteria
- •1\. Previous exposure to ACT\-246475\.
- •2\. Previous exposure to rifampicin within 3 months prior to Screening.
- •3\. Known hypersensitivity to P2Y12 receptor antagonists or rifampicin or to any of the rifamycins, or any of their excipients. ;Further exclusion criteria can be found in the protocol section 3\.2\.3\.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A single-center, randomized, double-blind, two-period cross-over study to investigate the effect of rifampicin on the pharmacokinetics of clazosentan in healthy male subjects.NL-OMON45870Idorsia Pharmaceuticals Ltd14
Completed
Not Applicable
A single-center, randomized, double-blind, double-dummy, placebo- and active-controlled, 4-way cross-over study to assess next-day driving performance following single and multiple evening administrations of ACT-541468 in middle-aged and elderly subjects.NL-OMON48154Idorsia Pharaceuticals Ltd.56
Completed
Not Applicable
BA/BE trials between two recombinant human bi-phasic insuliCTRI/2015/05/005827Wockhardt Limited56
Not yet recruiting
Phase 1
A Phase I clinical trial to study the effect of two drugs, Insulin Glargine manufactured by BioGenomics limited and Lantus® by comparing pharmacokinetic and pharmacodynamic properties, safety and tolerability in healthy male volunteers.CTRI/2022/09/045313BioGenomics Ltd
Recruiting
Phase 1
Phase-I clinical trial of Stelis Insulin Glargine injection 100IU/mL in healthy adultsCTRI/2020/12/030079Stelis Biopharma Pvt Ltd